Business Context and Reporting Period
Company: Retractable Technologies, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 4, 2005
Event: Entry into a Material Definitive Agreement (License Agreement) with Baiyin Tonsun Medical Device Co., Ltd. ("BTMD").
Key Financial Metrics and Agreement Terms
This filing details a licensing agreement rather than standard periodic financial results. Key financial terms include:
- Upfront Deposit: BTMD obligated to pay a $100,000 deposit within 30 days of the effective date.
- Royalty Structure (Quarterly):
- 2.5 cents per unit for 1/2 cc, 3 cc, and 5 cc syringes.
- 3.5 cents per unit for 1 cc and 10 cc syringes.
- Payment Terms: Royalties paid in US dollars, free of tax/tariff deductions. No royalty due until products are sold, except on unsold inventory upon termination.
- Performance Milestones (Termination Rights): Retractable Technologies may terminate if BTMD fails to generate royalties for:
- 25,000,000 units in 2006.
- 50,000,000 units in 2007.
- 100,000,000 units per year thereafter.
Note: The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures for the company.
Material Changes and Strategic Developments
The primary material change is the expansion of the company's market presence in the People's Republic of China (PRC) through a limited exclusive license granted to BTMD.
- Scope: BTMD has the right to manufacture and sell retractable needle syringes in the PRC for a three-year term.
- Company Rights: Retractable Technologies retains the right to manufacture and sell its own products in the PRC.
- Supply Chain Control: If BTMD cannot meet third-party demand, Retractable Technologies may license other manufacturers, subject to BTMD's right of first refusal (45-day window).
- Non-Compete: BTMD is prohibited from selling products to specific competitors for resale in the PRC, including Becton Dickinson, B. Braun, Terumo, OMI, and Tyco.
Outlook, Risks, and Contingencies
- Revenue Outlook: Royalty receipts are anticipated to begin no later than the first contract year, pending BTMD's facility construction.
- Patent Risk: The royalty obligation continues even if the company's patent rights in the PRC are found invalid or unenforceable.
- Termination Risks: The agreement can be terminated by Retractable Technologies for material breach (uncured after 45 days), failure to receive the deposit, or failure to meet unit volume milestones. Either party may terminate with 120 days' notice if ownership or control changes.
- Deposit Refund: The $100,000 deposit is refundable one year after receipt, less deductions for late or overdue royalty payments.
Investor Verification Checklist
- Confirm receipt of the $100,000 deposit from BTMD within the 30-day window.
- Monitor BTMD's facility construction progress to validate the timeline for royalty commencement.
- Track quarterly sales volume in the PRC to ensure BTMD meets the escalating unit milestones (25M, 50M, 100M) to avoid contract termination.
- Verify that BTMD is not distributing products to the listed competitors (Becton Dickinson, B. Braun, etc.).
- Review future filings for actual royalty revenue recognition once sales begin.